News round-up by DDW’s Megan Thomas for 11-15 October
For this week’s drug discovery round up, DDW’s Megan Thomas has selected five stories that showcase how organisations and collaboration within the drug discovery industry can provide researchers and drug developers with the tools they need to move forward with life-saving treatments.
Therapeutics research partnership to access induced Pluripotent Stem Cells
Bone Therapeutics and Implant Therapeutics have signed a research evaluation agreement to enable Bone Therapeutics to access, evaluate and materially transfer Implant Therapeutics’ Induced Pluripotent Stem Cell (iPSC) lines, media, differentiation protocols and expertise.
Collaboration offers high throughput 3D cell screening solution
UPM Biomedicals has entered into an agreement with PerkinElmer to act as a distributor of the UPM GrowDex and GrowDase range of products. This new collaboration will offer researchers a complete solution for high throughput screening (HTS) of 3D cell cultures in early drug discovery, combining PerkinElmer’s cell imaging and automation solutions and knowledge with UPM’s animal-free 3D reagent offerings and expertise.
WHO recommends GSK malaria vaccine for children at risk
The World Health Organization (WHO) has recommended GlaxoSmithKline (GSK)’s RTS,S malaria vaccine to be given to children living in sub-Saharan Africa who are at risk of contracting Malaria.
Neuroscience collaboration expands to include novel cell type
Evotec has expanded its collaboration with Bristol Myers Squibb to include a new cell type. The collaboration was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases.
‘Gut bugs’ can drive prostate cancer growth and treatment resistance
A team of scientists from The Institute of Cancer Research, London, the Institute of Oncology Research in Bellinzona, Switzerland and the Swiss Federal Institute of Technology revealed in a new study how gut bacteria contribute to the progression of advanced prostate cancers and their resistance to hormone therapy by providing an alternative source of growth-promoting androgens, or male hormones.
